Melodiol Global Health Ltd
ASX:ME1

Watchlist Manager
Melodiol Global Health Ltd Logo
Melodiol Global Health Ltd
ASX:ME1
Watchlist
Price: 0.001 AUD Market Closed
Market Cap: 1.1m AUD

Melodiol Global Health Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Melodiol Global Health Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Melodiol Global Health Ltd
ASX:ME1
Net Income (Common)
-AU$52.4m
CAGR 3-Years
-19%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Net Income (Common)
-AU$93.8m
CAGR 3-Years
31%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Net Income (Common)
AU$149.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Net Income (Common)
-AU$86.4m
CAGR 3-Years
-87%
CAGR 5-Years
-39%
CAGR 10-Years
-56%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Net Income (Common)
-AU$64.3m
CAGR 3-Years
-39%
CAGR 5-Years
-56%
CAGR 10-Years
N/A
Nyrada Inc
ASX:NYR
Net Income (Common)
-AU$4.8m
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
N/A
No Stocks Found

Melodiol Global Health Ltd
Glance View

Market Cap
1.1m AUD
Industry
Pharmaceuticals

Melodiol Global Health Ltd is a AU-based company operating in Pharmaceuticals industry. Melodiol Global Health Limited, formerly Creso Pharma Limited, is an Australia-based cannabis company. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. The company cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc., it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.

ME1 Intrinsic Value
Not Available

See Also

What is Melodiol Global Health Ltd's Net Income (Common)?
Net Income (Common)
-52.4m AUD

Based on the financial report for Dec 31, 2023, Melodiol Global Health Ltd's Net Income (Common) amounts to -52.4m AUD.

What is Melodiol Global Health Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-26%

Over the last year, the Net Income (Common) growth was -60%. The average annual Net Income (Common) growth rates for Melodiol Global Health Ltd have been -19% over the past three years , -26% over the past five years .

Back to Top